Mycophenolate mofetil treatment in patients with limited cutaneous systemic sclerosis is linked to a reduced need for escalation of vasoactive or vasodilator therapies for vascular complications.

Researchers conducted an open-label, pragmatic crossover study of 20 patients (all female) with systemic sclerosis at a single center who were on a stable MMF dose (1.5-2 g/day) for the last 3 months ...

Systemic sclerosis is a complex autoimmune condition marked by aberrant immune activation, widespread fibrosis and vasculopathy that affect the skin and multiple internal organs. The disease manifests ...